Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy

Blood. 2017 Mar 9;129(10):1397-1401. doi: 10.1182/blood-2016-10-745273. Epub 2017 Jan 12.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / administration & dosage
  • Azacitidine / analogs & derivatives*
  • Blood Cells* / metabolism
  • Blood Cells* / pathology
  • Decitabine
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / blood
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / pathology
  • Male
  • Mutation*
  • Myelodysplastic Syndromes* / blood
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / pathology
  • Neoplasm Proteins* / blood
  • Neoplasm Proteins* / genetics

Substances

  • Neoplasm Proteins
  • Decitabine
  • Azacitidine